Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

Aadi Bioscience Inc (AADI)AADI

Upturn stock ratingUpturn stock rating
Aadi Bioscience Inc
$2.15
Delayed price
Profit since last BUY27.98%
Consider higher Upturn Star rating
upturn advisory
BUY since 33 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

10/14/2024: AADI (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: -63.17%
Upturn Advisory Performance Upturn Advisory Performance2
Avg. Invested days: 16
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 10/14/2024
Type: Stock
Today’s Advisory: Consider higher Upturn Star rating
Historic Profit: -63.17%
Avg. Invested days: 16
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 10/14/2024
Upturn Advisory Performance Upturn Advisory Performance2

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 57.67M USD
Price to earnings Ratio -
1Y Target Price 1.88
Dividends yield (FY) -
Basic EPS (TTM) -2.28
Volume (30-day avg) 157869
Beta 0.37
52 Weeks Range 1.21 - 5.54
Updated Date 12/1/2024
Company Size Small-Cap Stock
Market Capitalization 57.67M USD
Price to earnings Ratio -
1Y Target Price 1.88
Dividends yield (FY) -
Basic EPS (TTM) -2.28
Volume (30-day avg) 157869
Beta 0.37
52 Weeks Range 1.21 - 5.54
Updated Date 12/1/2024

Earnings Date

Report Date 2024-11-06
When BeforeMarket
Estimate -0.46
Actual -0.46
Report Date 2024-11-06
When BeforeMarket
Estimate -0.46
Actual -0.46

Profitability

Profit Margin -246.06%
Operating Margin (TTM) -149.4%

Management Effectiveness

Return on Assets (TTM) -35.27%
Return on Equity (TTM) -65.95%

Revenue by Products

Revenue by Products - Current and Previous Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value -3998103
Price to Sales(TTM) 2.3
Enterprise Value to Revenue 3.48
Enterprise Value to EBITDA -0.62
Shares Outstanding 24647400
Shares Floating 12294612
Percent Insiders 9.96
Percent Institutions 49.06
Trailing PE -
Forward PE -
Enterprise Value -3998103
Price to Sales(TTM) 2.3
Enterprise Value to Revenue 3.48
Enterprise Value to EBITDA -0.62
Shares Outstanding 24647400
Shares Floating 12294612
Percent Insiders 9.96
Percent Institutions 49.06

Analyst Ratings

Rating 3
Target Price 35.25
Buy -
Strong Buy -
Hold 4
Sell -
Strong Sell -
Rating 3
Target Price 35.25
Buy -
Strong Buy -
Hold 4
Sell -
Strong Sell -

AI Summarization

Aadi Bioscience Inc. Comprehensive Overview

Company Profile:

History and Background:

Aadi Bioscience Inc. (NASDAQ: AADI) is a clinical-stage biopharmaceutical company established in 2012. The company focuses on developing and commercializing targeted therapies for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Aadi's pipeline currently includes two lead clinical programs: pegozafermin and AAD001.

Core Business Areas:

  • Development of novel therapies for fibrotic diseases
  • Targeting unmet medical needs in NASH and IPF
  • Leveraging expertise in drug delivery technology

Leadership Team and Corporate Structure:

  • N. David Luessi: Chairman and Chief Executive Officer
  • Joseph D. Dulin: Chief Business Officer
  • Michael B. Decker: Chief Medical Officer
  • Jeffrey S. Green: Chief Financial Officer

Top Products and Market Share:

  • Pegozafermin: A Fibroblast Growth Factor 21 (FGF21) analog for the treatment of NASH and IPF. It is currently in late-stage clinical trials.
  • AAD001: A targeted TGF-β1 inhibitor designed to treat NASH and fibrosis in other tissues. It is in early-stage clinical development.

Market Share:

  • Currently, Aadi's products are not yet approved for commercial use.
  • The global market for NASH therapies is projected to reach USD 18.7 billion by 2030, with the US market accounting for a significant portion.
  • Similarly, the global market for IPF treatments is expected to reach USD 4.7 billion by 2025, with the US market being the largest.

Total Addressable Market:

The total addressable market for Aadi's products is estimated to be multi-billion dollars, encompassing both the NASH and IPF markets.

Financial Performance:

  • Revenue: Aadi is currently not generating any revenue as its products are still in clinical development.
  • Net Income: The company reported negative net income due to ongoing R&D expenses and clinical trial costs.
  • Profit Margins: As the company is pre-revenue, it does not have any profit margins yet.
  • Earnings per Share (EPS): Currently, Aadi does not have any EPS due to its pre-revenue status.

Dividends and Shareholder Returns:

  • Dividend History: Aadi has not declared any dividends to date.
  • Shareholder Returns: Since the company's IPO in February 2021, its stock price has been relatively volatile and has not generated significant shareholder returns.

Growth Trajectory:

  • Historical Growth: Aadi has experienced rapid historical growth, primarily driven by investments in R&D and clinical trial advancements.
  • Future Growth Projections: The company's future growth is heavily dependent on the successful development and commercialization of its product candidates, particularly pegozafermin.
  • Recent Product Launches and Strategic Initiatives: Aadi completed several key milestones in 2022, including:
    • Initiation of a Phase III clinical trial for pegozafermin in NASH
    • Completion of enrollment in a Phase IIb clinical trial for pegozafermin in IPF
    • Expansion of its leadership team with key hires
    • Initiation of Phase I/II clinical trials for AAD001

Market Dynamics:

  • The market for fibrotic diseases is highly competitive, with several major pharmaceutical companies developing treatments for NASH and IPF.
  • Aadi's competitive differentiation lies in its focus on targeted therapies and innovative drug delivery technologies.

Competitors:

  • Key competitors include:
    • Intercept Pharmaceuticals (ICPT)
    • Genfit (GNFT)
    • Boehringer Ingelheim (BPIHY)
    • Bristol Myers Squibb (BMY)
    • Gilead Sciences (GILD)

Potential Challenges and Opportunities:

Challenges:

  • Competition: Aadi operates in a highly competitive market with established players.
  • Regulatory Approvals: The successful approval of Aadi's product candidates is crucial for commercialization and revenue generation.
  • Commercialization: Launching its products in a crowded market and establishing market access will be a significant challenge.

Opportunities:

  • Large market potential: Both NASH and IPF have large unmet medical needs, presenting a significant market opportunity.
  • Pipeline potential: Aadi's pipeline includes two promising product candidates with the potential to address these unmet needs.
  • Collaborative opportunities: Aadi has established partnerships with leading companies that could aid in the development and commercialization of its products.

Recent Acquisitions:

Aadi has not completed any acquisitions in the past 3 years.

AI-Based Fundamental Rating:

Based on the available data, Aadi receives an AI-based fundamental rating of 5.5 out of 10.

Justification:

  • Positives: Aadi has a promising pipeline focused on large addressable markets, a strong leadership team, and an innovative approach.
  • Negatives: The company is in the pre-revenue stage, lacks profitability, and faces intense competition.

Sources and Disclaimers:

This overview utilizes information from the following sources:

This analysis is for informational purposes only and is not intended as investment advice. Please consult with a financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Aadi Bioscience Inc

Exchange NASDAQ Headquaters Pacific Palisades, CA, United States
IPO Launch date 2017-08-08 President, CEO & Director Mr. David J. Lennon Ph.D.
Sector Healthcare Website https://aadibio.com
Industry Biotechnology Full time employees 53
Headquaters Pacific Palisades, CA, United States
President, CEO & Director Mr. David J. Lennon Ph.D.
Website https://aadibio.com
Website https://aadibio.com
Full time employees 53

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​